We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

128 hedge funds and large institutions have $1.04B invested in Aclaris Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more call options, than puts

Call options by funds: $483K | Put options by funds: $362K

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

8% more capital invested

Capital invested by funds: $957M → $1.04B (+$78.3M)

3.32% more ownership

Funds ownership: 95.35% → 98.67% (+3.3%)

1% more funds holding

Funds holding: 127 → 128 (+1)

33% less funds holding in top 10

Funds holding in top 10: 9 → 6 (-3)

Holders
128
Holders Change
+1
Holders Change %
+0.79%
% of All Funds
2.06%
Holding in Top 10
6
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
13
Increased
45
Reduced
37
Closed
11
Calls
$483K
Puts
$362K
Net Calls
+$121K
Net Calls Change
+$116K

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.7M
2
BlackRock
BlackRock
New York
+$4.48M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$3.07M
4
Walleye Capital
Walleye Capital
New York
+$2.4M
5
HighTower Advisors
HighTower Advisors
Illinois
+$2.16M

Top Sellers

1
BI
BVF Inc
California
-$11.3M
2
CC
Commodore Capital
New York
-$8.53M
3
Holocene Advisors
Holocene Advisors
New York
-$6.39M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$6M
5
ACM
Aisling Capital Management
New York
-$3.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$86.4M +$32.7M +2,030,160 +59%
BlackRock
2
BlackRock
New York
$80.1M +$4.48M +278,361 +6%
VA
3
VR Adviser
New York
$71.9M – – –
RCM
4
RA Capital Management
Massachusetts
$69.3M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$62.4M – – –
BI
6
BVF Inc
California
$51.6M -$11.3M -700,000 -18%
Vanguard Group
7
Vanguard Group
Pennsylvania
$49.2M +$3.07M +190,546 +6%
FCMI
8
Foresite Capital Management IV
California
$44.2M – – –
O
9
OrbiMed
New York
$43.4M – – –
B
10
Braidwell
Connecticut
$37.7M +$38.5M +2,393,985 New
CC
11
Commodore Capital
New York
$29.6M -$8.53M -530,336 -22%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$28.1M -$1.14M -70,651 -4%
Holocene Advisors
13
Holocene Advisors
New York
$26.2M -$6.39M -397,243 -19%
State Street
14
State Street
Massachusetts
$20.5M +$4.87K +303 +0%
FCMV
15
Foresite Capital Management V
California
$19.8M – – –
LCM
16
Laurion Capital Management
New York
$18.9M -$1.65M -102,823 -8%
Deutsche Bank
17
Deutsche Bank
Germany
$18.5M +$140K +8,696 +0.7%
TCM
18
TCG Crossover Management
California
$18M – – –
Renaissance Technologies
19
Renaissance Technologies
New York
$17.7M -$1.02M -63,426 -5%
Citadel Advisors
20
Citadel Advisors
Florida
$16.9M -$698K -43,377 -4%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$16.7M +$483K +30,025 +3%
GPP
22
Great Point Partners
Connecticut
$16.1M – – –
VC
23
Vivo Capital
California
$14.2M – – –
Fidelity Investments
24
Fidelity Investments
Massachusetts
$12.2M -$6M -372,863 -33%
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$11M – – –
1
2 3 4 5

ACRS Hedge Fund Activity: Q4 2022 in Review

128 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2022, worth a combined $1.04B — up 8.2% from $957M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ACRS positions and 11 closed out — a net gain of 2 holders — while 45 added to existing stakes and 37 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $32.7M. The largest seller was BVF Inc, cutting an estimated $11.3M.

  • 128 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2022, up from 127 in Q3 2022.
  • Funds reported $1.04B of Aclaris Therapeutics stock for Q4 2022, up 8.2% quarter-over-quarter.
  • 13 funds opened new Aclaris Therapeutics positions in Q4 2022 and 11 closed out, a net change of +2 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2022 was Wellington Management Group, an estimated $32.7M added.
  • The largest Aclaris Therapeutics seller in Q4 2022 was BVF Inc, an estimated $11.3M sold.

Based on aggregated 13F filings for Q4 2022.